Advanced Drug Delivery Systems: New Development, New Technologies

Published by: BCC Research

Published: Oct. 1, 2006 - 176 Pages

Table of Contents

INTRODUCTION

STUDY OBJECTIVES

REASONS FOR DOING THIS STUDY

CONTRIBUTIONS OF THE STUDY AND FOR WHOM

SCOPE OF THE STUDY

METHODOLOGY

INFORMATION SOURCES

ABOUT THE AUTHOR

RELATED BCC REPORTS

BCC ONLINE SERVICES

DISCLAIMER

EXECUTIVE SUMMARY

Summary Table: U.S. MARKET FORECAST OF ADVANCED DRUG DELIVERY SYSTEMS THROUGH 2011 ($ BILLIONS)

Summary Figure: U.S. MARKET FOR ADVANCED DRUG DELIVERY SYSTEMS 2004-2011 ($ BILLIONS)

OVERVIEW

DOSAGE FORMS

DIFFERENT TYPES OF DOSAGE FORMS

WHAT IS DRUG DELIVERY?

ROUTES OF DRUG DELIVERY

TECHNOLOGIES FOR DRUG DELIVERY

Sustained Release

Delayed Release

Prodrugs

Implants and Pumps for Drug Delivery

Targeted Delivery Systems

Receptor-Mediated Targeted Drug Delivery

CLASSIFICATION OF DRUG DELIVERY SYSTEMS

REGULATORY ISSUES

THE ROLE OF REGULATORY AUTHORITIES IN DRUG DELIVERY

Table 1 REGULATORY ACTION TAKEN FOR SAFE DRUG USAGE FOR DRUG DELIVERY SYSTEMS

USE OF EXCIPIENTS

INDUSTRY STRUCTURE

DRUG DELIVERY SYSTEMS PRODUCT SEGMENTS

SUSTAINED RELEASE ORAL DOSAGE FORMS

DIFFUSIONAL AND DISSOLUTION SYSTEMS

MARKET LEADERS

Table 2 MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED RELEASE ORAL DOSAGE FORMS, 2005

Table 3 U.S. MARKET FOR SUSTAINED RELEASE ORAL DOSAGE FORMS BY MANUFACTURER, 2005 (%)

Figure 1 U.S. MARKET SHARE FOR SUSTAINED RELEASE ORAL DOSAGE FORMS BY MANUFACTURER, 2005 (%)

SUSTAINED RELEASE INJECTABLE DOSAGE FORMS

MARKET LEADERS

Table 4 MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED RELEASE INJECTABLE DOSAGE FORMS, 2005

Table 5 U.S. SUSTAINED RELEASE INJECTABLE DOSAGE FORM MARKET BY MANUFACTURER, 2005 (%)

Figure 2 U.S. SUSTAINED RELEASE INJECTABLE DOSAGE FORMS MARKET BY MANUFACTURER, 2005 (%)

SUSTAINED RELEASE TOPICAL DOSAGE FORMS

MARKET LEADERS

Table 6 MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED RELEASE TOPICAL DOSAGE FORMS, 2005

Table 7 U.S. MARKET FOR SUSTAINED RELEASE TOPICAL DOSAGE FORMS BY MANUFACTURER, 2005 (%)

Figure 3 U.S.MARKET FOR SUSTAINED RELEASE TOPICAL DOSAGE FORMS BY MANUFACTURER, 2005 (%)

IMPLANTS AND IUDS

MARKET LEADERS

Table 8 MAJOR SUPPLIERS AND MANUFACTURERS OF IMPLANTS AND IUDS

Table 9 U.S. MARKET FOR IMPLANTS AND IUDS BY MANUFACTURER, 2005 (%)

Figure 4 U.S. MARKET FOR IMPLANTS AND IUDS BY MANUFACTURER, 2005 (%)

TRANSDERMAL DRUG DELIVERY SYSTEM (TDDS)

MARKET LEADERS

Table 10 MAJOR SUPPLIERS AND MANUFACTURERS OF TRANSDERMAL DRUG DELIVERY SYSTEMS, 2005

Table 11 U.S. MARKET FOR PATCH-DELIVERED DRUGS USED IN TRANSDERMAL DRUG DELIVERY SYSTEMS BY TYPE, 2005 (%)

Figure 5 U.S MARKET FOR PATCH DELIVERED DRUGS USED IN TRANSDERMAL DRUG DELIVERY SYSTEMS BY TYPE, 2005 (%)

Table 12 U.S. MARKET FOR SUPPLIERS AND MANUFACTURERS OF TDDS, 2005 (%)

Figure 6 U.S. MARKET FOR TDDS BY MANUFACTURER, 2005 (%)

TARGETED DELIVERY SYSTEMS

LIPOSOMES

MARKET LEADERS

Table 13 MAJOR SUPPLIERS AND MANUFACTURERS OF LIPOSOMES, 2005

Table 14 U.S. LIPOSOME DRUG MARKET BY TYPE, 2005 (%)

Figure 7 U.S LIPOSOME DRUG MARKET BY TYPE, 2005 (%)

Table 15 U.S. LIPOSOME MARKET BY MANUFACTURER, 2005 (%)

Figure 8 U.S. LIPOSOME MARKET BY MANUFACTURER, 2005 (%)

NANOPARTICLES

Table 16 MAJOR SUPPLIERS AND MANUFACTURERS OF NANOPARTICLES, 2005

Table 17 U.S. NANOPARTICLE MARKET BY MANUFACTURER, 2005 (%)

Figure 9 U.S. NANOPARTICLE MARKET BY MANUFACTURER, 2005 (%)

POLYMERS

MARKET LEADERS

Table 18 MAJOR SUPPLIERS AND MANUFACTURERS OF POLYMERS, 2005

MONOCLONAL ANTIBODIES

MARKET LEADERS

Table 19 MAJOR SUPPLIERS AND MANUFACTURERS OF MONOCLONAL ANTIBODIES, 2005

Table 20 U.S. MARKET FOR MONOCLONAL ANTIBODIES BY MANUFACTURER, 2005 (%)

Figure 10 U.S. MARKET FOR MONOCLONAL ANTIBODIES, BY MANUFACTURER, 2005 (%)

PEGNOLOGY

MARKET LEADERS

Table 21 MAJOR SUPPLIERS AND MANUFACTURERS OF PEGNOLOGY, 2005

Table 22 U.S. MARKET FOR PEGNOLOGY BY MANUFACTURER, 2005 (%)

Figure 11 U.S. MARKET FOR PEGNOLOGY BY MANUFACTURER, 2005 (%)

TRANSMUCOSAL DRUG DELIVERY SYSTEMS

INHALATION SYSTEMS

MARKET LEADERS

Table 23 MAJOR SUPPLIERS AND MANUFACTURERS OF INHALATION SYSTEMS, 2005

Table 24 U.S. MARKET FOR INHALATION SYSTEMS BY MANUFACTURER, 2005 (%)

Figure 12 U.S. MARKET FOR INHALATION SYSTEMS BY MANUFACTURER, 2005 (%)

BUCCAL DELIVERY

MARKET LEADERS

Table 25 MAJOR SUPPLIERS AND MANUFACTURERS OF BUCCAL DELIVERY SYSTEMS, 2005

Table 26 U.S. MARKET FOR BUCCAL DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)

Figure 13 U.S. MARKET SHARE FORBUCCAL DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)

RECTAL DELIVERY

MARKET LEADERS

Table 27 MAJOR SUPPLIERS AND MANUFACTURERS OF RECTAL DELIVERY SYSTEMS, 2005

Table 28 U.S. MARKET FOR RECTAL DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)

Figure 14 U.S. MARKET FOR RECTAL DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)

VAGINAL DELIVERY

MARKET LEADERS

Table 29 MAJOR SUPPLIERS AND MANUFACTURERS OF VAGINAL DELIVERY SYSTEMS, 2005

Table 30 U.S. MARKET FOR VAGINAL DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)

Figure 15 U.S. MARKET FORVAGINAL DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)

OCULAR DELIVERY

MARKET LEADERS

Table 31 MAJOR SUPPLIERS AND MANUFACTURERS OF OCULAR DELIVERY SYSTEMS, 2005

Table 32 U.S. MARKET FOR OCULAR DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)

Figure 16 U.S. MARKET FOROCULAR DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)

OTHERS

VACCINES

POLYCLONAL ANTIBODIES

FACTORS GOVERNING DEMAND AND USE

IMPROVING EFFICACY

ENVIRONMENTAL CONCERNS

BENEFITS OF DRUG DELIVERY

Compliance

Efficacy and Safety

Benefits to Pharmaceutical and Biotech Companies

Rescuing Research and Development Dropouts

Reducing Side Effects

TECHNOLOGY

NEW PRODUCT DEVELOPMENTS

Table 33 DEVELOPMENTS IN SUSTAINED RELEASE ORAL DOSAGE FORMS

Table 34 DEVELOPMENTS IN SUSTAINED RELEASE INJECTABLE DOSAGE FORMS

Table 35 DEVELOPMENTS IN SUSTAINED RELEASE TOPICAL DOSAGE FORMS

Table 36 DEVELOPMENTS IN TRANSDERMAL DRUG DELIVERY SYSTEMS

Table 37 DEVELOPMENTS IN LIPOSOMES

Table 38 DEVELOPMENTS IN NANOPARTICLES

Table 39 DEVELOPMENTS IN POLYMER

Table 40 DEVELOPMENTS IN MONOCLONAL ANTIBODIES

Table 41 DEVELOPMENTS IN PEGNOLOGY

Table 42 DEVELOPMENTS IN INHALATION SYSTEMS

Table 43 DEVELOPMENTS IN BUCCAL DELIVERY

Table 44 DEVELOPMENTS IN VAGINAL DELIVERY

Table 45 DEVELOPMENTS IN OCULAR DELIVERY

Table 46 DEVELOPMENTS IN VACCINE DELIVERY

MARKETS FOR DRUG DELIVERY TECHNOLOGY

SUSTAINED RELEASE ORAL DOSAGE FORM

PELLETIZED PULSATILE DELIVERY SYSTEM

SINGLE COMPOSITION OSMOTIC TABLET SYSTEM

SOLUBILITY MODULATING HYDROGEL SYSTEM

DELAYED PULSATILE HYDOGEL SYSTEM (DPHS)

STABILIZED PELLET DELIVERY SYSTEM

GRANULATED MODULATING HYDROGEL SYSTEM

PELLETIZED TABLET SYSTEM

POROUS TABLET SYSTEM

STABILIZED TABLET DELIVERY SYSTEM

DIRECTLY COMPRESSIBLE HYDROGEL SYSTEM

MODULATING MATRIX SYSTEM

PULSATILE ENTERIC COATING SYSTEM

PELLETIZED DELIVERY SYSTEM

Table 47 U.S. MARKET FORECAST FOR SUSTAINED RELEASE ORAL DOSAGE FORMS, THROUGH 2011 ($ BILLIONS)

Figure 17 U.S. MARKET FOR SUSTAINED RELEASE ORAL DOSAGE FORMS, 2004-2011 ($ BILLIONS)

SUSTAINED RELEASE INJECTABLE DOSAGE FORM

Table 48 U.S. MARKET FORECAST FOR SUSTAINED RELEASE INJECTABLE DOSAGE FORMS, THROUGH 2011 ($ BILLIONS)

Figure 18 U.S. MARKET FOR SUSTAINED RELEASE INJECTABLE DOSAGE FORMS ($ BILLIONS)

SUSTAINED RELEASE TOPICAL DOSAGE FORMS

Table 49 U.S. MARKET FORECAST FOR SUSTAINED RELEASE TOPICAL DOSAGE FORMS, THROUGH 2011 ($ MILLIONS)

Figure 19 U.S. MARKET FOR SUSTAINED RELEASE TOPICAL DOSAGE FORMS, 2004-2011 ($ MILLIONS)

IMPLANTS AND INTRAUTRINE DEVICES (IUDS)

Table 50 U.S. MARKET FORECAST FOR IMPLANTS AND IUDS, THROUGH 2011 ($ BILLIONS)

Figure 20 U.S. MARKET FOR IMPLANTS AND IUDS, 2004-2011 ($ BILLIONS)

TRANSDERMAL DRUG DELIVERY SYSTEMS

Table 51 U.S. MARKET FORECAST FOR TDDS, THROUGH 2011 ($ BILLIONS)

Figure 21 U.S. MARKET FOR TDDS, 2004-2011 ($ BILLIONS)

TARGETED DELIVERY SYSTEMS

Table 52 U.S. MARKET FORECAST FOR TARGETED DELIVERY SYSTEMS, THROUGH 2011 ($ MILLIONS)

Figure 22 U.S. MARKET FOR TARGETED DELIVERY SYSTEMS 2004-2011 ($ MILLIONS)

TRANSMUCOSAL DELIVERY SYSTEMS

Table 53 U.S. MARKET FORECAST FOR TRANSMUCOSAL DELIVERY SYSTEMS, THROUGH 2011 ($ MILLIONS)

Figure 23 U.S. MARKET FOR TRANSMUCOSAL DELIVERY SYSTEMS, 2004-2011 ($ MILLIONS)

PATENTS

PATENTS BY YEAR

Table 54 ANNUAL NUMBER OF PATENTS, 2003-2006

Figure 24 ANNUAL NUMBER OF PATENTS, 2003-2006 (UNITS)

Figure 25 ANNUAL NUMBER OF PATENTS, 2003-2005 (%)

PATENTS BY TECHNOLOGY

Table 55 DRUG DELIVERY PATENTS BY CATEGORY, 2003-2006

Figure 26 NUMBER OF DRUG DELIVERY PATENTS BY CATEGORY, 2003-2006 (UNITS)

Figure 27 DRUG DELIVERY PATENTS BY CATEGORY, 2003-2006 (%)

SIGNIFICANT PATENTS OF 2006

Table 56 SIGNIFICANT PATENTS FOR DRUG DELIVERY, 2006

PATENTS BY COMPANY

Table 57 U.S. PATENTS BY COMPANY, 2003-2006 (UNITS)

PATENTS BY COUNTRY

Table 58 NUMBER OF DRUG DELIVERY PATENTS BY COUNTRY, 2003-2006

Table 59 TRENDS OF DRUG DELIVERY PATENTS ISSUED BY COUNTRY, 2003-2006 (UNITS/%)

PATENTS BY ASSIGNEE

Table 60 SHARES OF U.S. PATENTS BY ASSIGNEE, 2003-2006 (UNIT/%)

Figure 28 SHARES OF U.S. PATENTS BY ASSIGNEE, 2003-2006 (UNITS)

Figure 29 SHARES OF U.S. PATENTS BY ASSIGNEE, 2003-2006 (%)

MARKETS BY PRODUCT

MARKETS BY PRODUCT

Table 61 U.S. MARKET FOR DRUG DELIVERY SYSTEMS BY PRODUCT SEGMENT, 2005 (%)

CARDIOVASCULAR

Table 62 U.S. MARKET FORECAST FOR CARDIOVASCULAR DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)

Figure 30 U.S. MARKET FOR CARDIOVASCULAR DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)

ONCOLOGY

Table 63 U.S. MARKET FORECAST FOR ONCOLOGY DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)

Figure 31 U.S. MARKET FOR ONCOLOGY DRUG DELIVERY SYSTEM, 2004-2011 ($ BILLIONS)

UROLOGY

Table 64 U.S. MARKET FORECAST FOR UROLOGY DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)

Figure 32 U.S. MARKET FOR UROLOGY DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)

DIABETES

Table 65 U.S. MARKET FORECAST FOR DIABETES DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)

Figure 33 U.S. MARKT FOR DIABETES DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)

RESPIRATORY

Table 66 U.S. MARKET FORECAST FOR RESPIRATORY DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)

Figure 34 U.S. MARKET FOR RESPIRATORY DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)

ANTI-INFLAMMATORY AND ALLERGY DRUG DELIVERY

Table 67 U.S. MARKET FORECAST FOR ANTI-INFLAMMATORY AND ALLERGY DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)

Figure 35 U.S. MARKET FOR ANTI-INFLAMMATORY AND ALLERGY DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)

ANTIBIOTICS

Table 68 U.S. MARKET FORECAST FOR ANTIBIOTIC DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)

Figure 36 U.S. MARKET FOR ANTIBIOTIC DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)

ANTI-ANXIETY AND ANTI-DEPRESSANTS

Table 69 U.S. MARKET FORECAST FOR ANTIANXIETY AND ANTIDEPRESSANT DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)

Figure 37 U.S. MARKET FOR ANTI-ANXIETY AND ANTI-DEPRESSANT DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)

HORMONES AND GYNECOLOGY

Table 70 U.S. MARKET FOR HORMONE AND GYNECOLOGY DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)

Figure 38 U.S. MARKET FOR HORMONES AND GYNECOLOGY DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)

OPHTHALMIC

Table 71 U.S. MARKET FORECAST FOR OPHTHALMIC DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)

Figure 39 U.S. MARKET FOR OPHTHALMIC DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)

IMMUNE DISEASES

Table 72 U.S. MARKET FORECAST FOR IMMUNE DISEASEDRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)

Figure 40 U.S. MARKET FOR IMMUNE DISEASEDRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLION)

OTHERS

Table 73 U.S. MARKET FORECAST FOR OTHERS CATEGORY IN DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)

Figure 41 U.S. MARKET FOR OTHERS CATEGORY IN DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)

Table 74 U.S. MARKET SHARES OF DEVELOPMENTS IN DRUG DELIVERY SYSTEMS, 2005 (%)

INTERNATIONAL ASPECTS

ASIA

EUROPE

REGIONAL COMPARISONS

Table 75 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS, 2005 (%)

Figure 42 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS, 2005 (%)

SUSTAINED RELEASE DOSAGE FORM (ORAL, INJECTABLE, TOPICAL) DRUG DELIVERY SYSTEMS

Table 76 GLOBAL MARKET FORECAST FOR SUSTAINED RELEASE DOSAGE (ORAL, INJECTABLE, TOPICAL) DRUG DELIVERY SYSTEMS BY REGION, THROUGH 2011 ($ BILLIONS)

Figure 43 GLOBAL MARKET FOR SUSTAINED RELEASE DOSAGE (ORAL, INJECTABLE, TOPICAL) DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)

IMPLANTS AND IUDS DRUG DELIVERY SYSTEMS

Table 77 GLOBAL MARKET FORECAST FOR IMPLANT AND IUD DRUG DELIVERY SYSTEMS BY REGION, THROUGH 2011 ($ BILLIONS)

Figure 44 GLOBAL MARKET FOR IMPLANTS AND IUD DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)

TRANSDERMAL DRUG DELIVERY SYSTEMS

Table 78 GLOBAL MARKET FORECAST FOR TRANSDERMAL DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)

Figure 45 GLOBAL MARKET FORECAST FOR TRANSDERMAL DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)

TARGETED DRUG DELIVERY SYSTEM, THROUGH 2011

Table 79 GLOBAL MARKET FORECAST FOR TARGETED DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)

Figure 46 GLOBAL MARKET FOR TARGETED DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)

GLOBAL MARKET FOR Transmucosal Drug Delivery SYSTEMS THROUGH 2011

Table 80 GLOBAL MARKET FORECAST FOR TRANSMUCOSAL DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)

Figure 47 GLOBAL MARKET FOR TRANSMUCOSAL DRUG DELIVERY SYSTEMS 2004-2011 ($ BILLION)

COMPANY PROFILES

ABBOTT LABORATORIES

APP-ABRAXIS PHARMACEUTICAL PRODUCTS

ASTRAZENECA PHARMACEUTICALS

ALKERMES

ADVANCED POLYMER PHARMA INC. (A.P. PHARMA)

AVENTIS PHARMACEUTICAL INC.

AKORN INC.

ANTIGENICS INC.

ARADIGM CORP.

ANDRX CORP. (ACQUIRED BY WATSON IN 2006)

BAYER CORP.

BIOVAIL CORP.

BERLEX LABORATORIES, INC.

BIOSANTE PHARMACEUTICALS, INC.

CARDINAL HEALTH, INC.

ELAN

ENZON, INC.

EURAND

GENENTECH INC.

GILEAD

JOHNSON & JOHNSON

KV PHARMACEUTICAL CO.

3M PHARMACEUTICALS

MEDIMMUNE, INC.

MGI PHARMA

MYLAN LABORATORIES INC.

NEKTAR THERAPEUTICS

NOVEN PHARMACEUTICALS, INC.

NOVAVAX, INC.

PFIZER INC.

PROTEIN DESIGN LABS

QLT USA INC.

SONTRA MEDICAL CORP.

SCHERING-PLOUGH CORP.

SOUTHERN RESEARCH INSTITUTE

SKYEPHARMA

WATSON PHARMACEUTICALS, INC.

WYETH

Abstract

• The U.S. sales of advanced drug delivery systems were over $54.2 billion in 2004. In 2005 they reached $64.1 billion and will eventually grow to $74.4 billion by the end of 2006. Over 5 years, this market will continue to grow at an average annual growth rate (AAGR) of 15.6% to reach $153.5 billion by 2011.
• The largest sector of the market consists of sustained release/implants/transdermal drug delivery systems, with more than 50% of the total U.S. market in 2005. Through the forecast period this sector will gradually give way to targeted drug delivery systems, which should control almost 48% of the market in 2011.
• Targeted drug delivery has the highest growth rate, with a 23.3% AAGR through 2011. The next highest are transmucosal drug delivery systems, with 15.3%.

• An overview of the major types of drug delivery systems used in the health industry
• Analysis of each technology with an in-depth look at manufacturers, the new products, sales estimates, market projections and market share information
• Discussion of the technological issues, including the latest trends and developments
• Forecasts of the U.S. market and its various sectors, with 5-year projections to 2011
• Profiles of the major players within the industry and a detailed patent analysis.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.